Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6555503 | 0.92 | DHFR (0.55) | DHFR | |
| SCHEMBL6555093 | 0.88 | DHFR (0.56) | DHFR | |
| SCHEMBL7570643 | 0.87 | DHFR (0.52) | DHFR | |
| SCHEMBL6555330 | 0.87 | DHFR (0.53) | DHFR | |
| SCHEMBL6556505 | 0.86 | DHFR (0.51) | DHFR | |
| SCHEMBL6555338 | 0.86 | DHFR (0.51) | DHFR | |
| SCHEMBL6556388 | 0.86 | DHFR (0.52) | DHFR | |
| SCHEMBL6557365 | 0.85 | DHFR (0.56) | DHFR | |
| SCHEMBL6555546 | 0.84 | DHFR (0.49) | DHFR | |
| SCHEMBL6873327 | 0.83 | DHFR (0.49) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1230224-B1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| US-6821980-B1 | Substituted 5-benzyl-2,4-diaminopyrimidines | BASILEA PHARMACEUTICA AG (CH) | 2004-11-23 | — | — | US | disclosed |
| US-20040048875-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. | 2004-03-11 | — | — | US | disclosed |
| EP-1230224-A1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032633-A1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048875-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | HRH4, HRH2, HRH3 | DHFR 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.